Avelumab (anti-PD-L1)

製品コードA2015 別名: MSB0010718C

製品コード：A2015 純度：99.99%

Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.

サイズ	価格(税別)	在庫状況
1mg	JPY 44500	国内在庫なし(納期7~10日)
5mg	JPY 146500	国内在庫あり
1mg*5	JPY 146500	お問い合わせ
1mg*25	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（2）

カスタマーフィードバック1例

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99.99% タンパク質濃度： 3.2mg/ml 内毒素：＜1EU/mg

99.99

PD-1/PD-L1阻害剤の選択性比較

生物活性

製品説明	Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.

In Vitro
In Vitro	Co-incubating chordoma cells with brachyury-specific CD8+ T cells results in significant upregulation of PD-L1 on the tumor cells, mediated by the CD8+ T cells' IFN-γ production, and increases sensitivity of chordoma cells to avelumab-mediated ADCC. Residential cancer stem cell subpopulations of chordoma cells are also killed by avelumab-mediated ADCC to the same degree as non-cancer stem cell populations. As a monotherapy for chordoma, avelumab may enable endogenous NK cells, while in combination with T-cell immunotherapy, such as a vaccine, avelumab may enhance NK-cell killing of chordoma cells via ADCC.^[1]
細胞実験	Objective: Antibody-dependent cellular cytotoxicity assay Cells: UM-Chor1 cells Concentrations: 2 μg/mL Incubation Time: 30 min Method: To examine the relationship between a CSC subpopulation and ADCC activity, UM-Chor1 cells are left untreated or treated with 50 ng/mL of IFN-γ for 24 h. Cells are then plated as targets at 50,000 cells/well in 6-well round-bottom culture plates and incubated with 2 μg/mL of avelumab at room temperature for 30 min. NK cells are added at 2500,000 cells/well at an E:T ratio of 50:1. After 4 h, tumor cells are harvested and stained with antibodies for flow cytometry. Reference: https://pubmed.ncbi.nlm.nih.gov/27172898 Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

In Vivo
In Vivo	An aggressive, bioluminescent orthotopic bladder cancer model, MB49 tumor cells transfected with luciferase (MB49^luc) is used to study the antitumor effects of avelumab. MB49^luc bladder tumors are highly positive for the expression of PD-L1 and avelumab administration induces significant (P<0.05) antitumor effects.^[2]
動物試験	Objective: Measurement of individual tumors Animal Models: 16- to 18-week-old female C57BL/6 mice Formulation: DPBS Dosages: 400 μg/100 μL Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/26921031/ Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

参考
[1] Rika Fujii, et al. Oncotarget. 2016 Jun 7;7(23):33498-511. [2] Amanda J Vandeveer, et al. Cancer Immunol Res. 2016 May;4(5):452-62.

参考

製品説明

CAS No.	1537032-82-8
Formulation	100 mM Pro-Ac, 20 mM Arg, pH 5.0
Isotype	Human IgG1
Source	Human
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping	Shipped under low temperature conditions

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須